Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Epie Boven

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Idrugs : the Investigational Drugs Journal|December 1, 2004
American Association for Cancer Research - 93rd Annual Meeting. 6-10 April 2002, San Francisco, CA, USAEpie Boven
The Journal of Urology|June 23, 2009
Re: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick And S. C. Campbell. J Urol 2009; 181: 518-523Astrid A M van der Veldt, Epie Boven, Axel Bex
International Journal of Clinical Oncology|March 1, 2008
Retroperitoneal mature teratoma after orchidectomy for a stage IB pure embryonal testicular carcinomaAart Beeker, Epie Boven, Pierre Lefesvre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Unusual presentation of granulosa cell tumor of the ovaryMaurice J D L van der Vorst, Maaike C G Bleeker, Epie Boven
Biochemical Pharmacology|June 5, 2003
Cytosolic beta-glycosidases for activation of glycoside prodrugs of daunorubicinMichelle de Graaf, Herbert M Pinedo, Razi Quadir, et al.
Current Pharmaceutical Design|June 8, 2002
Beta-glucuronidase-mediated drug releaseMichelle de Graaf, Epie Boven, Hans W Scheeren, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2003
Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case reportMiranda Verschraagen, Epie Boven, Ivon Zegers, et al.
The Journal of Urology|February 24, 2010
Re: Surgical resection of renal cell carcinoma after targeted therapyA. A. Thomas, B. I. Rini, A. J. Stephenson, J. A. Garcia, A. Fergany, V. Krishnamurthi, A. C. Novick, I. S. Gill, E. A. Klein, M. Zhou and S. C. Campbell J Urol 2009; 182: 881-886Axel Bex, Astrid A M van der Veldt, Epie Boven, et al.
Biochemical Pharmacology|May 7, 2002
Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxelGeertruida M Kolfschoten, Theresia M Hulscher, Monique C A Duyndam, et al.
Biochemical Pharmacology|July 23, 2008
Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motilityMarcel N A Bijman, Maria P A van Berkel, Geerten P van Nieuw Amerongen, et al.
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Idrugs : the Investigational Drugs Journal|December 1, 2004
American Association for Cancer Research - 93rd Annual Meeting. 6-10 April 2002, San Francisco, CA, USAEpie Boven
The Journal of Urology|June 23, 2009
Re: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick And S. C. Campbell. J Urol 2009; 181: 518-523Astrid A M van der Veldt, Epie Boven, Axel Bex
International Journal of Clinical Oncology|March 1, 2008
Retroperitoneal mature teratoma after orchidectomy for a stage IB pure embryonal testicular carcinomaAart Beeker, Epie Boven, Pierre Lefesvre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Unusual presentation of granulosa cell tumor of the ovaryMaurice J D L van der Vorst, Maaike C G Bleeker, Epie Boven
Biochemical Pharmacology|June 5, 2003
Cytosolic beta-glycosidases for activation of glycoside prodrugs of daunorubicinMichelle de Graaf, Herbert M Pinedo, Razi Quadir, et al.
Current Pharmaceutical Design|June 8, 2002
Beta-glucuronidase-mediated drug releaseMichelle de Graaf, Epie Boven, Hans W Scheeren, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2003
Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case reportMiranda Verschraagen, Epie Boven, Ivon Zegers, et al.
The Journal of Urology|February 24, 2010
Re: Surgical resection of renal cell carcinoma after targeted therapyA. A. Thomas, B. I. Rini, A. J. Stephenson, J. A. Garcia, A. Fergany, V. Krishnamurthi, A. C. Novick, I. S. Gill, E. A. Klein, M. Zhou and S. C. Campbell J Urol 2009; 182: 881-886Axel Bex, Astrid A M van der Veldt, Epie Boven, et al.
Biochemical Pharmacology|May 7, 2002
Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxelGeertruida M Kolfschoten, Theresia M Hulscher, Monique C A Duyndam, et al.
Biochemical Pharmacology|July 23, 2008
Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motilityMarcel N A Bijman, Maria P A van Berkel, Geerten P van Nieuw Amerongen, et al.
Pageof 8